TMC Life Sciences Berhad (0101.KL)
- Previous Close
0.4400 - Open
0.4400 - Bid 0.4350 x --
- Ask 0.4400 x --
- Day's Range
0.4400 - 0.4450 - 52 Week Range
0.3650 - 0.6950 - Volume
58,000 - Avg. Volume
138,380 - Market Cap (intraday)
775.137M - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1800 - Earnings Date --
- Forward Dividend & Yield 0.00 (1.11%)
- Ex-Dividend Date Dec 5, 2024
- 1y Target Est
--
TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara (THKD), a medical bedded center located in Selangor. Its THKD provides women and children health, cancer, orthopedics, ENT, head and neck laser, gastro, hepato, urology, fertility health services. In addition, the company's reproductive treatment comprises in-vitro fertilisation, preimplantation genetic testing, fertility preservation, laparoscopic surgery, surgical sperm retrieval, and donation programmes; and offers fertility consultancy services; laboratory and embryology; traditional and complementary; pharmacy services and products; and management support and multi-disciplinary tertiary care services. Further, it operates a women's clinic and fertility centers, as well as provides related services; develops, markets, and manages healthcare programs; and operates pharmacy store. Additionally, the company engages in the research and development activities; and property investment activities. TMC Life Sciences Berhad was founded in 1994 and is based in Petaling Jaya, Malaysia. The company is a subsidiary of Sasteria (M) Pte. Ltd.
www.tmclife.comRecent News: 0101.KL
View MorePerformance Overview: 0101.KL
Trailing total returns as of 5/27/2025, which may include dividends or other distributions. Benchmark is FTSE Bursa Malaysia KLCI (^KLSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0101.KL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0101.KL
View MoreValuation Measures
Market Cap
766.43M
Enterprise Value
838.95M
Trailing P/E
59.46
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35
Price/Book (mrq)
0.90
Enterprise Value/Revenue
2.57
Enterprise Value/EBITDA
18.06
Financial Highlights
Profitability and Income Statement
Profit Margin
0.68%
Return on Assets (ttm)
0.49%
Return on Equity (ttm)
0.25%
Revenue (ttm)
326.39M
Net Income Avi to Common (ttm)
2.21M
Diluted EPS (ttm)
-2.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
116.76M
Total Debt/Equity (mrq)
22.25%
Levered Free Cash Flow (ttm)
-19.75M